Regulatory Affairs Scope of Work Template for External Support

Most regulatory sourcing problems start before any external provider is contacted, whether that provider is a consultant, advisory firm, specialist contractor, or regulatory services firm. They start with a need that is real but underspecified: “we need help with our submission,” “we should talk to someone about MDR,” or “we need a regulatory strategy.” Each of these is a starting point, not a scope. A provider cannot credibly price, staff, or commit to a need that has not been defined, and a company cannot compare providers fairly when each is responding to a different interpretation of the same vague request.

A scope of work is the document that turns an internal regulatory need into something an external provider can respond to and a company can evaluate. It does not need to be long. It needs to be specific about the few variables that determine who is a fit, how much the work costs, and how success will be judged. A good scope of work is also the foundation for everything downstream: comparable proposals, a clean contract, and an objective basis for judging whether the delivered work matches what was agreed.

This guide sets out how to write that defined scope. It is deliberately structured around the variables that matter most in regulatory work, because a generic project brief will miss them.

Why a vague need is expensive

An unscoped need is expensive in ways that are easy to underestimate, and the costs tend to surface late, when they are hardest to absorb.

It produces non-comparable responses. If one provider assumes a strategy memo, another assumes a full submission, and a third assumes ongoing support, their fees and timelines cannot be compared, and the company ends up normalizing apples and oranges. The selection decision then rests on which provider pitched most confidently rather than which fits best.

It attracts the wrong providers. Without product class, jurisdiction, and lifecycle detail, a brief may draw responses from capable firms with related but not directly relevant expertise, such as a trial-operations group responding to a strategy question, or a publishing specialist responding to a request that really requires senior judgment.

It defers the hard thinking to mid-project. Scope that is not defined up front tends to surface later as change requests, disputes, or rework, usually at the least convenient moment, such as in the weeks before a submission deadline. What looks like flexibility at the start often becomes friction and cost later.

It weakens the company’s position. When the scope is loose, the provider, not the company, effectively defines what the engagement covers, often in their own commercial interest. A clear scope keeps control of the engagement with the company.

The time spent defining scope is rarely wasted. It either produces a better engagement or reveals that the need is not yet ready to outsource, which is itself a valuable finding.

The variables that define regulatory scope

Regulatory work is specific. A good scope of work names the variables that determine fit, rather than describing the problem in general terms. The following are the variables that most reliably distinguish a fit from an adjacent provider.

Product class. Drug, biologic, medical device, in vitro diagnostic, combination product, digital health, or other product classes. This single variable changes the applicable framework, the relevant expertise, and often the entire provider shortlist. Device and drug pathways are not interchangeable, and a combination product may require both kinds of expertise.

Jurisdiction and authority. Which markets and which regulators: FDA, EMA and EU member states, MHRA, Swissmedic, PMDA, Health Canada, or others. Name the specific authority and any country-level requirements, because experience with one authority does not transfer automatically to another. A consultant deeply experienced with FDA interactions may have limited recent experience with EU member-state requirements, and vice versa. For EU device and IVD work, also specify the relevant notified body, national competent authority, conformity-assessment route, and any prior reviewer questions, audit observations, or compliance gaps.

Lifecycle stage. Pre-clinical, first-in-human, clinical development, submission and approval, post-approval maintenance, or remediation. The stage determines the kind of judgment and operational support required, and a provider strong at early strategy may not be the right choice for post-approval maintenance.

Nature of the work. Distinguish work requiring senior regulatory judgment, such as pathway selection, agency-meeting strategy, evidence interpretation, or risk framing, from execution-heavy work, such as publishing, submission assembly, country maintenance, or tracking. The same provider may do both, but they should be scoped and evaluated separately, because they require different experience levels and are priced differently.

Deliverables and acceptance criteria. What you will receive: a strategy memo, a gap assessment, an authored document, a submission-ready dossier, or named ongoing support. State the format, the expected level of detail, and how you will decide the work is complete, so that “done” is defined by the company rather than assumed by the provider.

Experience level and named team. Whether the work needs senior judgment, experienced execution, or both. Specify that you want to know who will actually do the work and how experienced they are, not just the firm name, particularly for work requiring senior judgment.

Timeline and dependencies. The deadline, the milestones, and the inputs, decisions, or authority timelines the work depends on. Many regulatory timelines also depend on authority processes outside anyone’s control, which should be acknowledged rather than assumed away.

Oversight model. How the work will be supervised, who owns final content, and how the provider integrates with your internal team or systems. Regulatory ownership and oversight generally remain with the sponsor, applicant, manufacturer, or marketing authorisation holder even when activities are outsourced; where responsibilities are delegated or formally transferred, that should be documented in the scope of work and contract, in line with applicable requirements.

Before and after: from vague request to provider-ready scope

The difference between an unscoped need and a scope of work is best seen in contrast.

A vague need reads: “We need help getting our device ready for Europe.” It names neither the device class, the specific regulation, the stage, nor the deliverable. Providers responding to it will each fill the gaps differently.

The same need, scoped, reads: “We need a gap assessment of the clinical evaluation documentation for a Class IIb device against current EU MDR expectations (Article 61 and Annex XIV), covering the clinical evaluation plan and report, the literature search and appraisal, intended-purpose and claims alignment, the link to the relevant general safety and performance requirements, and post-market clinical follow-up and surveillance inputs. The deliverable is a written report with a prioritized remediation plan, due within eight weeks and led by a consultant with recent notified-body interaction experience for this device class.”

Company identity, product identifiers, and sensitive commercial context, such as M&A, licensing, financing, or partnering activity, can be withheld until after you have selected a small group of suitable providers under NDA. The only exception may be minimal information a provider needs earlier to run a conflict check, meaning a check that the provider is not already advising a competitor or conflicted party.

The second version names product class, jurisdiction and framework, stage, the specific deliverable and its format, the timeline, the experience level required, and what can be shared now versus later. Every qualified provider responding to it will be answering the same question, and their responses will be comparable. The work of writing the second version is the work of sourcing well. It is also exactly the kind of scoped brief that can become a confidential RegSeek request, letting providers respond to the same defined need before any identities are revealed.

The same discipline applies across the rest of regulatory affairs, not only medtech. A drug chemistry, manufacturing and controls (CMC) need, scoped, reads: “We need a CMC regulatory gap assessment for an FDA IND amendment, focused on Module 3, the quality/CMC section of a drug dossier, the comparability rationale for a manufacturing change, and outstanding stability data, delivered as a risk-ranked memo and a document checklist within four weeks, led by a CMC regulatory specialist with recent IND experience.” A post-approval maintenance need, scoped, reads: “We need support for a regulatory variation to update the manufacturing site for an EU-authorised product, covering the variation classification, the required documentation, and submission through the relevant procedure, delivered as a submission-ready variation package within six weeks, with availability to respond to agency questions.”

A simple structure for the document

A scope of work does not need to be elaborate. A clear one-to-two page structure is usually enough.

The “in scope and out of scope” line is worth particular attention. Naming what is explicitly excluded prevents much of the scope creep that damages regulatory engagements later. If a related activity might reasonably be assumed to be included but is not, say so.

A copy-paste scope of work template

Use this as a starting point and delete what does not apply. The goal is specificity, not length.

Product / technology:
Product class (drug / biologic / device / IVD / combination / digital health / other):
Jurisdiction(s) and authority (plus notified body / competent authority for EU devices and IVDs):
Lifecycle stage:
Regulatory question / objective (stated as an outcome):
In scope:
Out of scope:
Deliverables and format:
Acceptance criteria (how you will decide the work is complete):
Required experience level and named delivery team:
Timeline, milestones, and dependencies (inputs, decisions, or authority timelines):
Fee basis (or request the provider's proposed basis with assumptions):
Oversight, content ownership, and confidentiality:
What can be shared now vs later:
Proposal requirements (what each provider should include in their response):

Common scoping mistakes to avoid

A few recurring mistakes undermine otherwise good briefs.

Describing activities instead of outcomes. “Support our submission” is an activity; “produce a submission-ready Module 3 (a drug CMC example) to the agreed standard by the deadline” is an outcome. The same holds across product types: for a device, “author the Clinical Evaluation Report to Annex XIV” is an outcome where “help with the CER” is not. Outcomes are easier to price, compare, and judge.

Leaving seniority implicit. A brief that does not specify seniority invites providers to staff the work in whatever way suits their economics. Naming the experience required for work requiring senior judgment keeps quality in the company’s control.

Confusing breadth with clarity. A long brief that rambles is not clearer than a short one that is specific. The goal is that two qualified providers would interpret the scope the same way, not that the document is exhaustive.

Ignoring dependencies. A scope that assumes instant inputs from the company and ignores authority timelines will produce optimistic, non-comparable proposals. Naming dependencies makes responses realistic.

Over-disclosing to scope well. Some companies feel they must reveal everything to get a good response. They do not. A precise regulatory description attracts the right providers without exposing sensitive commercial context, as discussed below.

Calibrating how much to disclose

A scope of work is also a disclosure decision. The more context a provider has, the better the response, but regulatory needs are often sensitive, touching M&A, licensing, financing, remediation work to fix regulatory gaps, or sensitive product issues that should not be signaled prematurely.

The practical answer is staged disclosure: sharing sensitive details only after providers are shortlisted. The initial brief can describe the need precisely in regulatory terms (product class, jurisdiction, stage, deliverable) without revealing company identity, the specific product, or the underlying commercial situation. More sensitive detail is shared as the process narrows to a shortlist under appropriate confidentiality. A confidential sourcing process where the company identity is masked and providers respond to the same structured brief is designed for exactly this balance: enough specificity to attract the right providers, without over-exposing the situation.

The test is whether each element of the brief is necessary for a provider to assess fit and respond. Regulatory specifics usually are; company identity and commercial context usually are not, at least not at the first stage.

What to ask providers to include in their response

A scope of work is only half of a good comparison; the other half is asking every provider to respond in the same shape. To make responses directly comparable, ask each provider to include:

• Their proposed approach and method.
• The named delivery team and relevant, recent experience.
• Key assumptions and what they would need from you before starting.
• Estimated timeline and earliest start date.
• Fee basis and estimate, with what is included and excluded.
• Dependencies and risks they foresee.
• Conflict-of-interest position and how confidentiality is handled.

Asking for the same elements turns a set of free-form pitches into structured, comparable responses, which is exactly what a brief-led process such as RegSeek’s expressions of interest (EOI) workflow is built to produce.

From defined scope to sourcing

Once the scope is written, it helps providers quote accurately, assign the right people, and explain their assumptions. Providers respond to the same defined request, which makes their approaches, assumptions, fees, and timelines genuinely comparable. The scope also becomes the reference point for evaluating proposals, for the eventual contract, and for judging whether the work delivered matches what was agreed.

It is also a living document in a limited sense. As the engagement proceeds and understanding develops, the scope may need to change, but a clear original scope means that change is visible and managed, through an explicit change process, rather than silent and disputed. That visibility is one of the main protections a good scope of work provides.

A good scope of work is the difference between a sourcing process that compares like with like and one that compares interpretations. It is the single highest-leverage document in regulatory sourcing.

Turn an unstructured need into a confidential sourcing process

You do not need a finished scope of work to start, and there are two ways in, depending on how well defined the need already is.

If you can describe the product, market, deliverable, timeline, and type of expertise required, use Shortlist & Connect. RegSeek’s structured request for proposal (RFP) builder turns that into a confidential request, keeps your company identity masked, and lets vetted providers respond with comparable expressions of interest (EOIs) covering approach, experience, fee, timeline, and availability. Posting, comparing, and shortlisting are free; you pay only when you choose to unlock selected providers and reveal identities.

If the need is complex, confidential, multi-market, or not yet clearly scoped, use RegSeek-Assisted Sourcing. It begins with a scoping call to refine the brief and define the right provider profile, then RegSeek runs confidential outreach to suitable providers, checks availability, conflicts, and confidentiality agreement readiness, and returns a curated shortlist with the rationale for each candidate, supporting you through comparison and selection.

For a focused question rather than a full project, Written Regulatory Advice or a Regulatory Expert Call gives you targeted input from a matched regulatory advisor or expert. In every case the goal is the same: turn an uncertain regulatory need into a controlled process where providers respond to the same defined request and your identity is unmasked only when you choose.

FAQ

What is a regulatory affairs scope of work?

A regulatory affairs scope of work is a short document that defines the product, jurisdiction, authority, lifecycle stage, activities, deliverables, timeline, required experience level, oversight model, and acceptance criteria for an outsourced regulatory project. Its purpose is to turn a vague need into a request that providers can price, staff, and compare against the same definition.

How detailed should a regulatory scope of work be?

Detailed enough that two qualified providers would interpret it the same way. In practice that means naming product class, jurisdiction and authority, lifecycle stage, deliverables, and acceptance criteria for deciding when the work is complete. One to two pages is usually sufficient; length is not the goal, specificity is.

What if we do not yet know enough to scope the work?

That is a common and legitimate position. In that case the first engagement may itself be a scoping or gap-assessment exercise, deliberately small and clearly bounded, after which a fuller scope can be written. Naming this as the objective is better than issuing a vague brief for the whole programme. If the uncertainty is mainly about how to define the work before approaching providers, RegSeek-Assisted Sourcing can begin with a scoping call to clarify the regulatory question and the right provider profile before any outreach starts.

How do we scope work without revealing sensitive context?

Describe the need in regulatory terms rather than commercial ones, and share sensitive details only after providers are shortlisted. Product class, jurisdiction, stage, and deliverable can usually be shared without identifying the company, product, or commercial backdrop, with more detail released to a shortlist under confidentiality.

Who should write the scope of work?

Whoever owns the regulatory need internally, with input from anyone who will oversee the work or rely on its output. Even when a company lacks deep regulatory expertise, drafting the scope internally, then refining it, keeps control of the engagement with the company rather than the provider. If internal expertise is thin, an initial scoping engagement can help define the larger scope.

Sources and Further Reading

• EUR-Lex, Regulation (EU) 2017/745 (EU MDR), current consolidated version - Article 61 and Annex XIV (on clinical evaluation requirements).
• European Commission, MDCG endorsed documents and guidance (clinical evaluation, PMCF, and related guidance).
• RegSeek, Regulatory Affairs Outsourcing in Life Sciences (on provider models and matching external support to the work type).

Need help with a similar regulatory sourcing decision? Submit a confidential brief →

← All resources